| 词条 | Solitomab |
| 释义 |
| type = mab | image = | alt = | mab_type = BiTE | source = o | target = EpCAM | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1005198-65-1 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = ZQQ51B5708 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | chemical_formula = | molecular_weight = }}Solitomab (INN) (MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.[1][2][3] Mechanism of actionLike other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.[1][4] This action mimics physiological processes observed during T cell attacks against tumor cells.[4] References1. ^1 {{cite journal|journal=Oncology NEWS International|volume=17|issue=6|date=1 June 2008|first=Caroline|last=Helwick|url=http://www.cancernetwork.com/display/article/10165/1165525|title=Novel BiTE antibody mediates contact between T cells and cancer cells}} {{monoclonals for tumors}}{{monoclonal-antibody-stub}}2. ^{{ClinicalTrialsGov|NCT00635596|Phase I Study of MT110 in Colorectal Cancer (CRC), Gastrointestinal (GI) and Lung Cancer (MT110-101)}} 3. ^{{Cite journal | first8 = D. | last9 = Volkland | last8 = Rau | first7 = S. | last7 = Mangold | first9 = J. | journal = Journal of Immunotherapy| pmid = 19609237 | issue = 5| pages = 452–464 | volume = 32 | last10 = Pflanz | first6 = R. | last6 = Lutterbuese | first1 = M. | first10 = S. | last2 = d'Argouges | last1 = Amann | last11 = Raum | year = 2009 | first11 = T. | last12 = Münz | first12 = M. | last13 = Kufer | first13 = P. | last14 = Schlereth | first14 = B. | last15 = Baeuerle | first15 = P. A. | last16 = Friedrich | first16 = M. | title = Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release | first2 = S. | last3 = Lorenczewski | last5 = Kischel | first5 = R. | first4 = K. | last4 = Brischwein | first3 = G. | doi = 10.1097/CJI.0b013e3181a1c097 }} 4. ^1 {{cite web|url=http://www.micromet.de/index.php?id=67|title=BiTE Antibody Platform|publisher=Micromet Inc}} 2 : Monoclonal antibodies|Experimental cancer drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。